Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B. Abergel A, et al. Among authors: reymond m. Liver Int. 2020 Aug;40(8):1853-1859. doi: 10.1111/liv.14502. Epub 2020 Jun 1. Liver Int. 2020. PMID: 32383275 Clinical Trial.
Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort).
Barré T, Pol S, Ramier C, Di Beo V, Carrat F, Bureau M, Bourlière M, Dorival C, Serfaty L, Asselah T, Boursier J, Marcellin F, Carrieri P, Fontaine H, Protopopescu C; ANRS/AFEF Hepather Study Group. Barré T, et al. Cannabis Cannabinoid Res. 2022 Oct;7(5):677-689. doi: 10.1089/can.2021.0094. Epub 2021 Oct 13. Cannabis Cannabinoid Res. 2022. PMID: 34648718 Free PMC article.
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.
Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-Astagneau E, Mathurin P, Marcellin F, Petrov-Sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C; ANRS/AFEF Hepather study group. Barré T, et al. J Cannabis Res. 2022 Jun 11;4(1):31. doi: 10.1186/s42238-022-00138-9. J Cannabis Res. 2022. PMID: 35690798 Free PMC article.
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Manlay L, Boschetti G, Pereira B, Flourié B, Dapoigny M, Reymond M, Sollelis E, Gay C, Boube M, Buisson A, Nancey S. Manlay L, et al. Among authors: reymond m. Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299. doi: 10.1111/apt.16377. Epub 2021 Apr 28. Aliment Pharmacol Ther. 2021. PMID: 33909920
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.
Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A; POPCUR study group. Bommelaer G, et al. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1553-1560.e1. doi: 10.1016/j.cgh.2019.08.041. Epub 2019 Aug 27. Clin Gastroenterol Hepatol. 2020. PMID: 31470175 Clinical Trial.
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
Lafeuille P, Hordonneau C, Vignette J, Blayac L, Dapoigny M, Reymond M, Rouquette O, Sollelis E, Boube M, Magnin B, Pereira B, Buisson A. Lafeuille P, et al. Among authors: reymond m. Aliment Pharmacol Ther. 2021 Mar;53(5):577-586. doi: 10.1111/apt.16232. Epub 2020 Dec 28. Aliment Pharmacol Ther. 2021. PMID: 33368525
308 results